Events

Careers with impact: working in ML applied drug discovery

One of the unexpected outcomes of the COVID-19 pandemic has been that it has made technology talent aware of the opportunities to use technology to tackle some of the world’s most important and pressing healthcare challenges. 


4th November 2020 | 5.30pm UK time - 12:30pm NYC Time

While interest in joining the industry has increased, many are prevented from taking the leap due to a belief that they do not possess the necessary scientific knowledge. This invisible door is preventing talented people from entering the industry. Worryingly, this problem could be amplified for women in tech, who are already less likely to apply for a role they’re not 100% qualified for.

This meetup will look to demystify AI in drug discovery in order to empower female tech talent to take the leap into this important growth industry. We will counter preconceptions that only those with scientific knowledge can join, by showcasing how we work at BenevolentAI, where we bring together cross-functional teams of machine learning engineers, AI scientists, data scientists and informaticians to co-create our AI platform for drug discovery, alongside our seasoned drug discoverers.

This is a free event and we’d love you to join us for an evening of open dialogue and ideas exchange. 

→ Register here

Event agenda

17:30 – Grab a drink of your choice, get comfy and logon for an intro from Sam

17:35 – 19:55 – Panel discussion part I: countering preconceptions that only those with scientific knowledge can join the drug discovery industry

17:55 - 18:15 – Panel discussion part II: exploring the importance of diverse skills and experiences in AI applied drug discovery, and discussing practical actions to building diverse and inclusive teams.

18:15 - 18:20 – Q&As

18:20 - 18:50 – Split into virtual rooms for networking and a Q&A opportunity with the Benevolent team.


Speakers:

Ana Leite | Lead Bioinformatic Data Scientist

Aylin Cakiroglu | Senior AI Scientist

Paidi Creed | Director, AI Science

Saee Paliwal | Lead AI Scientist

Sam Coulter (Moderator) | Talent Acquisition Specialist


More Posts

You Might Also Like

News
BenevolentAI Appoints Daniel Neil as Chief Technology Officer
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Jan 21, 2022
Blog
World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19
The WHO has widened its COVID-19 treatment pool by adding baricitinib, the drug first identified as a COVID-19 treatment by BenevolentAI, to the top of its treatment guideline.
Jan 14, 2022
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
BenevolentAI and AstraZeneca add systemic lupus erythematosus and heart failure to their expanded AI drug discovery collaboration.
Jan 13, 2022
News
BenevolentAI to Present at the 40th Annual JP Morgan Healthcare Conference
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 6, 2022
Blog
It’s up to us: reflections on responsible innovation
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.
Dec 22, 2021
News
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca’s portfolio
Novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s AI-driven drug discovery platform, selected to enter AstraZeneca’s portfolio.
Dec 15, 2021